Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Slides:

Advertisements

Similar presentations

Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.

Advertisements

IDH1 mutant glioma cells are sensitive to TMZ

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.

WEE1 inhibition forces S-phase–arrested cancer cells into mitosis.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

BV6 increases tumor burden in bone.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

PDK1 regulates PLK1 in vivo and in vitro.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

nab-Paclitaxel targets the tumor epithelial cells.

BIRC6 confers resistance against cisplatin and oxaliplatin.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.

Treatment with MI-773 causes changes in p53 status.

Mechanism of piperlongumine induced Sp downregulation.

MMAE resistance and intracellular accumulation.

TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

PTENP1 sensitizes renal cancer cells to chemotherapy.

A, chemical structures of PRIMA-1 and PRIMA-1Met.

Sensor siRNAs can be used in high-order combinations.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

IL-13Rα2 promotes cell survival and proliferation.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

The AKT–mTOR pathway controls PD-L1 protein expression.

Tipifarnib and bortezomib are synergistic in cytotoxicity assays

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

ERK reactivation following EGFR TKI treatment.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. CDs with KRASG12C cooperatively sustain downstream.

Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy. Platinum-based chemotherapy.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

EGFR signaling regulates transcription of PDGFRβ gene.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

NRAS-mediated resistance to vemurafenib (Vem) is associated with restored glycolysis and can be overcome by combination with a glycolysis inhibitor. NRAS-mediated.

A, cell number was assessed 96 hours after exposure to indicated treatment in indicated cell models. A, cell number was assessed 96 hours after exposure.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Effect of bevacizumab on the proliferation of A2780 cells.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

ABT-888 sensitizes multiple ovarian cancer cell lines but not normal cells to FdUrd. ABT-888 sensitizes multiple ovarian cancer cell lines but not normal.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Frequency of CD4+CD25+FoxP3+ and CD4+CD25+CD127low T cells in unactivated PBMCs from healthy donors. Frequency of CD4+CD25+FoxP3+ and CD4+CD25+CD127low.

Frequency of CD4+CD25+FoxP3+, CD4+CD25+CD127low, and CD4+CD25+LAP+ T cells before and after treatment with anti–CTLA-4. Frequency of CD4+CD25+FoxP3+, CD4+CD25+CD127low,

Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced proliferation in HepG2 cells. Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

DQs have superior anticancer efficacy among dimeric antimalarials.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

Presentation transcript:

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. A, 794, AM38, and BT16 cells were treated with increasing doses of vemurafenib in media with and without 10 μmol/L CQ for 72 hours, and tritiated thymidine uptake assays were performed to assess cell proliferation. B, 794, AM38, and BT16 cells were treated with increasing doses of vemurafenib and CQ for 72 hours. Tritiated thymidine uptake assays were performed to assess cell proliferation. The Chou–Talalay equation was used to calculate combination index (CI) values. CI values less than 1, equal to 1, and more than 1 indicate synergism, additive effect, and antagonism, respectively. C and E, 794, AM38, and BT16 cells were treated with increasing doses of cisplatin or vinblastine in media with and without 20 μmol/L CQ for 72 hours, and cell viability was evaluated by MTS assay. D and F, 794, AM38, and BT16 cells were treated with increasing doses of cisplatin or vinblastine and CQ for 72 hours. MTS assays were performed to assess cell viability, and CI values were calculated. Jean M. Mulcahy Levy et al. Cancer Discovery 2014;4:773-780 ©2014 by American Association for Cancer Research